These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2043408)

  • 1. [A favorable response to the somatostatin analog SMS 201-995 in a patient with the carcinoid syndrome].
    Del Val A; Ponce J; Talens A; Martí-Bonmati L; Garrigues V; Berenguer J
    Rev Esp Enferm Dig; 1991 Mar; 79(3):215-7. PubMed ID: 2043408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Enteral hyperoxalosis due to therapy with a somatostatin analog].
    Ranft K; Eibl-Eibesfeldt B
    Dtsch Med Wochenschr; 1990 Feb; 115(5):179-81. PubMed ID: 2298134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
    Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
    N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SMS 201-995 and provocation tests in preparation of patients with carcinoids for surgery or hepatic arterial embolization.
    Ahlman H; Ahlund L; Dahlström A; Martner J; Stenqvist O; Tylén U
    Anesth Analg; 1988 Dec; 67(12):1142-8. PubMed ID: 2461665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of malignant carcinoid syndrome with a long-acting somatostatin analogue.
    Altman AR; Tschen JA; Rice L
    Arch Dermatol; 1989 Mar; 125(3):394-6. PubMed ID: 2923448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A prolonged-action somatostatin analog and carcinoid syndrome].
    Chayvialle JA
    Bull Acad Natl Med; 1989 May; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of carcinoid syndrome with a somatostatin analogue].
    Döbrönte Z; Stöckert A; Végh G; Varga L
    Orv Hetil; 1992 Mar; 133(12):731-4. PubMed ID: 1372969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment with octreotide (SMS 201-995) in a case of intestinal carcinoid tumor].
    Goñi F; Oleaga A; Goñi MJ; Monreal M; Yoldi A; González A; Llorente I; Moncada E
    Rev Clin Esp; 1991 Nov; 189(7):331-4. PubMed ID: 1722585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analogs of somatostatin and carcinoid tumors].
    Gutiérrez Rodero F; Morales Cano JM; de Blas Laborda C; González Barber A
    Med Clin (Barc); 1990 Jun; 95(2):78-9. PubMed ID: 2250512
    [No Abstract]   [Full Text] [Related]  

  • 10. [Therapy of metastatic carcinoid with the somatostatin analog octreotide and with recombinant interferon alfa 2b].
    Linkesch M; Kuzmits R; Geyer G
    Wien Klin Wochenschr; 1989 Jun; 101(13):455-7. PubMed ID: 2763566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Carcinoid tumor--diagnostic and therapeutic problems].
    Batowski S; Bielewicz A
    Pol Tyg Lek; 1994 Jun 6-13; 49(23-24):536-7. PubMed ID: 7675710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of somatostatin infusion in four patients with malignant carcinoid syndrome.
    Quatrini M; Basilisco G; Conte D; Bozzani A; Bardella MT; Bianchi PA
    Am J Gastroenterol; 1983 Mar; 78(3):149-51. PubMed ID: 6187212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment with a long-acting somatostatin analogue (SMS201-995) in a patient with malignant carcinoid syndrome.
    Tsuda M; Tamaki S; Iwasaki E; Murashima S; Deguchi K; Shirakawa S
    Jpn J Med; 1988 Aug; 27(3):311-6. PubMed ID: 3193661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management.
    Vinik AI; Thompson N; Eckhauser F; Moattari AR
    Acta Oncol; 1989; 28(3):389-402. PubMed ID: 2663049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin analogue (SMS 201-995) in patients with gastrinomas.
    Vinik AI; Tsai S; Moattari AR; Cheung P
    Surgery; 1988 Nov; 104(5):834-42. PubMed ID: 2903562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of carcinoid syndrome with ocreotide (SMS-201-995)].
    Rodríguez-García JL; Arechaga S; Fraile G; Serrano M
    Rev Clin Esp; 1992 Jul; 191(3):168. PubMed ID: 1380173
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome.
    Oberg K; Norheim I; Theodorsson E; Ahlman H; Lundqvist G; Wide L
    J Clin Endocrinol Metab; 1989 Apr; 68(4):796-800. PubMed ID: 2466045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful symptomatic treatment of malignant carcinoid syndrome with the somatostatin analogue SMS 201-995.
    van Houten AA; Nortier JW; Vendrik CP
    Neth J Med; 1988 Apr; 32(3-4):194-8. PubMed ID: 2896307
    [No Abstract]   [Full Text] [Related]  

  • 19. [Symptomatic treatment of the malignant carcinoid syndrome with octreotide].
    Alberts AS; Falkson G
    S Afr Med J; 1989 Jan; 75(1):30-1. PubMed ID: 2911781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Octreotide treatment of carcinoid hypertensive crisis.
    Warner RR; Mani S; Profeta J; Grunstein E
    Mt Sinai J Med; 1994 Sep; 61(4):349-55. PubMed ID: 7969229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.